Meny

Javascript is not activated in your browser. This website needs javascript activated to work properly.
Du är här

Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticles.

Författare:
  • Sissela Broos
  • Linda C Sandin
  • Jenny Apel
  • Thomas H Tötterman
  • Takami Akagi
  • Mitsuru Akashi
  • Carl Borrebaeck
  • Peter Ellmark
  • Malin Lindstedt
Publiceringsår: 2012
Språk: Engelska
Sidor: 6230-6239
Publikation/Tidskrift/Serie: Biomaterials
Volym: 33
Nummer: 26
Dokumenttyp: Artikel
Förlag: Elsevier

Sammanfattning

Agonistic anti-CD40 monoclonal antibodies (mAbs) hold great potential for cancer immunotherapy. However, systemic administration of anti-CD40 mAbs can be associated with severe side effects, such as cytokine release syndrome and liver damage. With the aim to increase the immunostimulatory potency as well as to achieve a local drug retention of anti-CD40 mAbs, we linked an agonistic mAb to immune activating amphiphilic poly(γ-glutamic acid) nanoparticles (γ-PGA NPs). We demonstrate that adsorption of anti-CD40 mAb to γ-PGA NPs (anti-CD40-NPs) improved the stimulatory capacity of the CD40 agonist, resulting in upregulation of costimulatory CD80 and CD86 on antigen-presenting cells, as well as IL-12 secretion. Interestingly, anti-CD40-NPs induced strong synergistic proliferative effects in B cells, possibly resulting from a higher degree of CD40 multimerization, enabled by display of multiple anti-CD40 mAbs on the NPs. In addition, local treatment with anti-CD40-NPs, compared to only soluble CD40 agonist, resulted in a significant reduction in serum levels of IL-6, IL-10, IL-12 and TNF-α in a bladder cancer model. Taken together, our results suggest that anti-CD40-NPs are capable of synergistically enhancing the immunostimulatory effect induced by the CD40 agonist, as well as minimizing adverse side effects associated with systemic cytokine release. This concept of nanomedicine could play an important role in localized immunotherapy of cancer.

Disputation

Nyckelord

  • Medicine and Health Sciences
  • Technology and Engineering
  • Cell
  • proliferation
  • Protein adsorption
  • Immunostimulation
  • Drug delivery
  • Nanoparticle

Övriga

Published
Yes
  • ISSN: 1878-5905

Box 117, 221 00 LUND
Telefon 046-222 00 00 (växel)
Telefax 046-222 47 20
lu [at] lu [dot] se

Fakturaadress: Box 188, 221 00 LUND
Organisationsnummer: 202100-3211
Om webbplatsen